RNADerm Therapeutics
Berkeley, US · Founded 2018 · Delaware corporation
Founders & leadership
AK
Aaron K. SatoNamed on SEC filing
MD
Mark de SouzaNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$750K disclosed across 1 round · 2019
▶$750KraisedMar 2019 · 3 investors · BiotechnologyRule 506(b)
▶$750KraisedMar 2019 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aaron K. SatoExecutive Officer, Director
- Mark de SouzaExecutive Officer, Director
- Offering amount
- $14.8M
- Amount sold
- $750K
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has RNADerm Therapeutics raised?
- RNADerm Therapeutics has disclosed $750K raised across 1 round.
- Where is RNADerm Therapeutics headquartered?
- RNADerm Therapeutics is headquartered in Berkeley, US.